<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03449732</url>
  </required_header>
  <id_info>
    <org_study_id>17/46/519</org_study_id>
    <nct_id>NCT03449732</nct_id>
  </id_info>
  <brief_title>Evaluation of the Pupil Dilation Reflex in Response to Noxious Stimulation in Anaesthetized Children. A Proof of Concept Trial</brief_title>
  <acronym>Pain@OR-kids</acronym>
  <official_title>Evaluation of the Pupil Dilation Reflex (PDR) Using a Pupillary Pain Index (PPI) Stimulation Protocol in Response to Noxious Stimulation in Anaesthetized Children. A Proof of Concept Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Antwerp</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Antwerp</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      After conduction a pilot study, pupillary dilation reflex (PDR) is measured in response to
      nociceptive stimulation perioperatively in infants, children and adolescents.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An infrared camera of the video pupillometer measures the pupillary dilation reflex (PDR) in
      response to incremental nociceptive stimuli. The PDR is a robust reflex, even in patients
      under general anesthesia, and may provide a potential evaluation of the autonomous
      nociceptive circuit. American Society of Anesthesiologists (ASA) classification I or II
      patients from the age of 28 days till 18 years undergoing elective surgery under general
      anesthesia are recruited. Enrolled patients perioperative undergo PDR measurement at 2
      different standardized times (before and after opioid administration) generated by an inbuilt
      pupillary pain index (PPI) protocol. PPI, as a surrogate for nociception includes noxious
      stimulations from 10 up to 60 milli ampere (mA) until pupil dilation is larger than 13% from
      baseline diameter. Therefore, no inappropriate high stimulation is executed.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 30, 2018</start_date>
  <completion_date type="Anticipated">June 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Stimulation Intensity</measure>
    <time_frame>During pupil measurements in the perioperative period</time_frame>
    <description>Necessary stimulation intensity to dilate the pupil more than 13%</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pupillary Pain Index score</measure>
    <time_frame>During pupil measurements in the perioperative period</time_frame>
    <description>Device specific PPI score defined in accordance to stimulation intensity necessary for pupil dilation more than 13%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>During PDR measurements</time_frame>
    <description>Hypertension as a common used parameter for perioperative nociceptive assessment defined as an increase in systolic blood pressure by &gt;10% of the initial systolic blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate</measure>
    <time_frame>During PDR measurements</time_frame>
    <description>Tachycardia as a common used parameter for perioperative nociceptive assessment</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Pain</condition>
  <condition>Monitoring, Intraoperative</condition>
  <arm_group>
    <arm_group_label>PDR measurement group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two measurements of PDR perioperatively before and after opioid administration in toddlers (28 days until 23 months)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PDR measurement group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two measurements of PDR perioperatively before and after opioid administration in children (2 until 11 years)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PDR measurement group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two measurements of PDR perioperatively before and after opioid administration in adolescents (12 until 18 years)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PDR measurement</intervention_name>
    <description>PDR measurement at two standardized times perioperatively:
Anesthetized subject by sevoflurane sedation until a minimum alveolar concentration (MAC) of at least 1,5 is reached
Administration of fentanyl 2Âµg/kg, in the absence of adjustments in sedation depth</description>
    <arm_group_label>PDR measurement group A</arm_group_label>
    <arm_group_label>PDR measurement group B</arm_group_label>
    <arm_group_label>PDR measurement group C</arm_group_label>
    <other_name>PPI assessment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Scheduled abdominal, urological or otorhinolaryngology surgery under general
             anaesthesia

          -  ASA I-II

        Exclusion Criteria:

          -  History of eye deformity, invasive ophthalmologic surgery

          -  Known cranial nerve(s) deficit

          -  Infection of the eye

          -  Predicted difficult airway management (Paediatric Difficult Airway Guidelines -
             Difficult Airway Society)

          -  Chronic opioid use (&gt;3 months)

          -  Ongoing treatment with beta-blockers, dopamine antagonists, topical atropine

          -  Preoperatively administrated benzodiazepins or antiemetics
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nathalie Kegels, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Antwerp</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vera Saldien, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital, Antwerp</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Davina Wildemeersch, MD</last_name>
    <phone>38215891</phone>
    <phone_ext>0032</phone_ext>
    <email>davina.wildemeersch@uza.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Guy Hans, MD, PhD</last_name>
    <phone>38213586</phone>
    <phone_ext>0032</phone_ext>
    <email>guy.hans@uza.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University hospital Antwerp</name>
      <address>
        <city>Edegem</city>
        <state>Antwerp</state>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Davina Wildemeersch, MD</last_name>
      <phone>03 821 58 91</phone>
      <phone_ext>0032</phone_ext>
      <email>davina.wildemeersch@uza.be</email>
    </contact>
    <contact_backup>
      <last_name>Guy Hans, MD,PhD</last_name>
      <phone>03 821 35 86</phone>
      <email>guy.hans@uza.be</email>
    </contact_backup>
    <investigator>
      <last_name>Davina Wildemeersch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nathalie Kegels, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Guy Hans, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vera Saldien, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 22, 2018</study_first_submitted>
  <study_first_submitted_qc>February 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 28, 2018</study_first_posted>
  <last_update_submitted>March 30, 2018</last_update_submitted>
  <last_update_submitted_qc>March 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Antwerp</investigator_affiliation>
    <investigator_full_name>Davina Wildemeersch</investigator_full_name>
    <investigator_title>Principle investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mydriasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

